Arcutis Biotherapeutics (ARQT) Stock Forecast & Price Target

Arcutis Biotherapeutics is viewed favorably because Zoryve is becoming a leading branded topical dermatology franchise with differentiated once-daily roflumilast across plaque psoriasis, atopic dermatitis, and seborrheic dermatitis, supported by strong potency and a favorable tolerability profile versus older PDE4 inhibitors and branded competitors. Commercial execution has been robust, with Zoryve sales rising from $29M in 2023 to $167M in 2024 and $372M in 2025, while 2Q26 sales reached $129.9M and total product revenue grew 59% year over year, leading management to raise 2026 net product sales guidance to $525M-$540M. The outlook is further strengthened by limited direct competition in seborrheic dermatitis, expanding psoriasis and pediatric opportunities, cash-flow positivity, and additional upside from vitiligo, hidradenitis suppurativa, and ARQ-234 clinical readouts.

Arcutis Biotherapeutics is viewed negatively because its growth thesis depends heavily on ZORYVE achieving broad adoption in a crowded topical dermatology market, yet reimbursement friction, intensive prior authorization, and direct competition from generics and Vtama could slow uptake. The company also still faces meaningful regulatory uncertainty, including pending approval for scalp psoriasis and a 2/23/27 PDUFA for Zoryve cream 0.05% in infants with atopic dermatitis, while vitiligo and HS are assigned 0% PoS until further clarity emerges. Even with 2026E Zoryve revenue guidance of $525–$540M, higher gross-to-net discounts, reliance on Interquim for manufacturing, and rising operating expenses point to pressure on net sales and a need for additional capital.